Tesaro

Tesaro Inc. is a pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer.

Tesaro, Inc.
TypeSubsidiary
IndustryPharmaceuticals
Founded2010 in Waltham, Massachusetts
Headquarters
Waltham Edit this on Wikidata
,
United States Edit this on Wikidata
ProductsVarubi
Number of employees
286 (2016)
ParentGSK
(2019–present)
Websitetesarobio.com

History

Tesaro was founded in 2010.[1] The company's first commercial product, Varubi, was approved by the FDA in October 2015.[2] As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD.[3] The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA.[4] In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer.[5] On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale.[5] On December 3, 2018, GSK announced it would acquire the company for $5.1 billion,[6] and the deal was completed on January 22, 2019.[7]

Products under development
  • Rolapitant – intravenous form in phase III clinical trials for use in chemotherapy-induced nausea and vomiting
  • Niraparib – PARP inhibitor in clinical trials for breast and ovarian cancer.[8]
  • TSR-042
  • TSR-022
  • Dostarlimab - In February 2023, the FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.

References
  1. "Tesaro". FierceBiotech. Retrieved 2017-02-25.
  2. "TESARO - Quarterly Report". Ir.tesarobio.com. Retrieved 2017-02-25.
  3. "TESARO - Annual Report". Ir.tesarobio.com. Retrieved 2017-02-25.
  4. ESARO (TSRO) Announces Priority FDA Review for Niraparib NDA, Street Insider, December 20, 2016, archived from the original on December 21, 2016, retrieved June 8, 2017{{citation}}: CS1 maint: bot: original URL status unknown (link)
  5. D. Rockoff, Jonathan; Cimilluca, Dana (May 31, 2017). "Tesaro Explores Sale". Wall Street Journal. New York City, New York. Retrieved June 1, 2017.
  6. "GSK slides after buying cancer firm Tesaro for hefty $5.1 billion". 3 December 2018 – via uk.reuters.com.
  7. "GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company". 22 January 2019.
  8. "2016 Press Release: Niraparib Significantly Improves Outcome of Ovarian Cancer Patients in Landmark Trial". ESMO. Retrieved 2017-02-25.
  • Official website
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.